International Journal of Gynecological Cancer

Targeted therapy for epithelial ovarian cancer: Current status and future prospects
pp. 701-734(34)
Authors: See H.T.; Kavanagh J.J.; Hu W.; Bast R.C.

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5
pp. 735-740(6)
Authors: Bookman M.A.; Greer B.E.; Ozols R.F.

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy
pp. 741-748(8)
Authors: Calhoun E.A.; Welshman E.E.; Chang C.-H.; Lurain J.R.; Fishman D.A.; Hunt T.L.; Cella D.

Molecular similarities between primary peritoneal and primary ovarian carcinomas
pp. 749-755(7)
Authors: Chen L.-M.; Yamada S.D.; Fu Y.-S.; Baldwin R.L.; Karlan B.Y.

Factors associated with non-epithelial ovarian cancer among Mexican women: A matched case-control study
pp. 756-763(8)
Authors: Sanchez-Zamorano L.M.; Salazar-Martinez E.; De Los Rios P.E.; Gonzalez-Lira G.; Flores-Luna L.; Lazcano-Ponce E.C.

Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum
pp. 764-770(7)
Authors: Look M.; Chang D.; Sugarbaker P.H.

Comparison of HGF (hepatocyte growth factor) levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts
pp. 771-775(5)
Authors: Baykal C.; Demirtas E.; Al A.; Ayhan A.; Yuce K.; Tulunay G.; Kose M.F.

Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer
pp. 776-784(9)
Authors: Ikeda K.; Sakai K.; Yamamoto R.; Hareyama H.; Tsumura N.; Watari H.; Shimizu M.; Minakami H.; Sakuragi N.

CYP1A1 polymorphism and risk of gynecological malignancy in Japan
pp. 785-790(6)
Authors: * T.S.; † E.N.; † T.S.; † N.S.; † S.F.

Total mesometrial resection: High resolution nerve-sparing radical hysterectomy based on developmentally defined surgical anatomy
pp. 791-803(13)
Authors: *¶ M.H.; † L.-C.H.; ‡ B.H.; * S.H.; § G.N.

A real time optoelectronic device as an adjunct to the Pap smear for cervical screening: A multicenter evaluation
pp. 804-811(8)
Authors: Singer A.; Coppleson M.; Canfell K.; Skladnev V.; Mackellar G.; Pisal N.; Deery A.

A new technique to map vulva microcirculation using laser Doppler perfusion imager
pp. 812-818(7)
Authors: Saravanamuthu J.; Seifalian A.M.; Reid W.M.; Maclean A.B.

Shanxi Province cervical cancer screening study II: Self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology
pp. 819-826(8)
Authors: Belinson J.L.; Qiao Y.L.; Pretorius R.G.; Zhang W.H.; Rong S.D.; Huang M.N.; Zhao F.H.; Wu L.Y.; Ren S.D.; Huang R.D.; Washington M.F.; Pan Q.J.; Li L.; Fife D.

Knowledge and practice about cervical cancer and Pap smear testing among patients at Kenyatta National Hospital, Nairobi, Kenya
pp. 827-833(7)
Authors: Gichangi P.; Estambale B.; Bwayo J.; Rogo K.; Ojwang S.; Opiyo A.; Temmerman M.

The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression, and cervical cancer
pp. 834-842(9)
Authors: Moodley M.; Sewart S.; Herrington C.S.; Chetty R.; Pegoraro R.; Moodley J.

The effect of codon 98 of the FHIT gene on cervical cancer in Korean women
pp. 843-848(6)
Authors: Jee S.H.; Um S.J.; Lee J.E.; Kim S.; Kim J.H.; Lee S.J.; Namkoong S.E.; Park J.S.

Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy
pp. 849-855(7)
Authors: Niibe Y.; Nakano T.; Ohno T.; Suzuki Y.; Oka K.; Tsujii H.

Significance of microvascular density (MVD) in cervical cancer recurrence
pp. 856-862(7)
Authors: Cantu De León D.; Lopez-Graniel C.; Frias Mendivil M.; Chanona Vilchis G.; Gomez C.; De La Garza Salazar J.

The value of pelvic and para-aortic lymphadenectomy in endometrial cancer to avoid unnecessary radiotherapy
pp. 863-869(7)
Authors: Lo K.W.K.; Cheung T.H.; Yu M.Y.; Yim S.F.; Chung T.K.H.

Oncoprotein profiles of primary peritoneal malignant mixed müllerian tumors
pp. 870-874(5)
Authors: Ng J.S.; Han A.C.; Edelson M.I.; Rosenblum N.G.

Gestational trophoblastic syndrome and human immunodeficiency virus (HIV) infection: A retrospective analysis
pp. 875-878(4)
Authors: Moodley M.; Moodley J.

Methylation status and expression of E-cadherin and cadherin-11 in gestational trophoblastic diseases
pp. 879-888(10)
Authors: * W.C.X.; † H.C.F.; † S.W.T.; * K.Y.K.C.; ‡ H.Y.S.N.; * P.M.C.; § C.D.M.; * A.N.Y.C.

A study of blood cross-matching requirements for surgery in gynecological oncology: Improved efficiency and cost saving
pp. 889-893(5)
Authors: Foley C.L.; Mould T.; Kennedy J.E.; Barton D.P.J.

Uterine inversion by a mixed müllerian tumor of the corpus
pp. 894-897(4)
Authors: Tjalma W.A.A.; Naik R.; Monaghan J.M.; De Barros Lopes A.

Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. A case report
pp. 898-900(3)
Authors: Hindenburg A.A.; Matthews L.

Endometrial carcinoma with recurrence in the incisional scar: A case report
pp. 901-903(3)
Authors: Joshi S.C.; Sharma D.N.; Khurana N.; Mohanta P.K.; Bahadur A.K.

Acute leukemia in pregnancy with ovarian metastasis: a case report and review of the literature
pp. 904-908(5)
Authors: Terek M.C.; Ozkinay E.; Zekioglu O.; Erhan Y.; Cagirgan S.; Pehlivan M.; Mgoyi L.

Endometrial cancer metastasis presenting as a grossly swollen toe
pp. 909-911(3)
Authors: Ali Z.A.; Wimhurst J.A.; Ali A.A.; Tempest M.E.; Edwards D.J.

Patient selection for neoadjuvant chemotherapy trials
pp. 912-913(2)
Authors: Narayan K.; Quinn M.A.

Laterally extended parametrectomy (LEP), the technique for radical pelvic side wall dissection: Feasibility, technique and results
pp. 914-917(4)
Authors: Pálfalvi L.; Ungár L.

Atlas of Procedures in Gynecologic Oncology: Memorial Sloan-Kettering Cancer Center
pp. 918-919(2)
Authors: Levine D.A.; Barakat R.R.; Hoskins W.J.